Printer Friendly


 KANSAS CITY, Kan., Oct. 5 /PRNewswire/ -- Syntro Corporation (NASDAQ: SYNT) today announced that its wholly owned subsidiary, SyntroVet Incorporated, has received United States Department of Agriculture (USDA) approval for its MaxiVac(TM)-FLU vaccine. An important new addition to SyntroVet's swine product line, MaxiVac-FLU is the first vaccine approved by the USDA for the prevention of disease caused by swine influenza virus (SIV). Swine flu is a highly infectious respiratory disease that affects over half of the swine herds in the U.S. SIV circulates in hog populations in all regions of the U.S. throughout the year.
 SyntroVet's strategy for further development of its swine vaccine line is to focus on diseases of major economic significance to the sophisticated pork producer. Swine flu is gaining increased recognition for the important role it plays in outbreaks of acute and chronic respiratory disease. Respiratory disorders account for more than 25 percent of the costs associated with disease in pigs, which typically results in higher mortality, reduced weight gain, increased feed consumption, lower meat quality and additional disease control expenditures. As modern management practices encourage the further concentration of animals in large commercial operations, the risk for rapid spread of infectious respiratory disease and its resulting losses can be expected to grow.
 Typically, SIV spreads through an entire herd within one to three days and immediately reduces the efficiency and profitability of the operation. Swine flu is characterized by fever, loss of appetite, visible weight loss, coughing and respiratory distress. Infected animals take longer to reach market weight, require additional labor and other expenditures for disease treatment and control and, in the end, consume more feed per pound of gain. Swine flu outbreaks often are associated with breeding problems as well; abortions, stillbirths, infertility, piglet mortality and weak litters routinely are reported following flu episodes. A flu outbreak also increases the likelihood, the severity and the duration of outbreaks of other diseases.
 SyntroVet's MaxiVac-FLU is an important new herd health management tool that offers practical protection from the economic impact of swine flu. A special oil-in-water adjuvant system enables the inactivated viral vaccine to deliver strong immunity against disease caused by the most prevalent SIV strain found in the U.S. MaxiVac-FLU can be used in all pigs of weaning age or older.
 Syntro Corporation is a Kansas City and San Diego-based biotechnology company engaged in the development, manufacturing and commercialization of innovative vaccines for the animal health market.
 -0- 10/5/93
 /CONTACT: J. Donald Todd, president and CEO, or Susan H. Strobel, vice president and CFO of Syntro, 913-888-8876/

CO: Syntro Corporation; SyntroVet Incorporated ST: Kansas, California IN: MTC AGR SU:

GK-SH -- NY011 -- 8713 10/05/93 08:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 5, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters